Medicine for artificial intelligence can reach the markets in 2030

It is likely that the first developed medicine with artificial intelligence techniques is likely to reach the commercial markets by the end of the contract, according to the head of an emerging company specializing in the discovery of medication based on artificial intelligence techniques. “I would be surprised if we didn’t see it during the next five or six years,” said Alex Zafuronkov, CEO of “Insilico Medicine”, in an interview with Bloomberg TV. He added: “I hope to be the first to achieve this achievement. We are working on more than 40 internal programs, but no one knows what’s going to happen.” The pharmaceutical industry has always promoted the capabilities of artificial intelligence to accelerate the rate of research and development and reduce its costs, although none of them have been approved so far. Takeda Pharmaceutical, the final stages of clinical tests for psoriasis treatment, were selected by artificial intelligence as its data is expected this year. The role of artificial intelligence in the development of medicine, although most companies currently use artificial intelligence in a fragmented way, but which distinguishes “ensheleko”, the integration of technology into each stage of the development of the drug, from the status of the target of hypotheses, to the improvement of the drug composition to produce, according to Zaforonkov. The operations of “Ecsikeliko” are being distributed by the United States, China, the Middle East and Canada, and the company recently filed its inclusion on the Hong Kong Stock Exchange after completing a special financing round, increasing its evaluation to more than one billion dollars.